| Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas JK Lee, J Lee, S Kim, S Kim, J Youk, S Park, Y An, B Keam, DW Kim, ... Journal of clinical oncology 35 (26), 3065-3074, 2017 | 390 | 2017 |
| Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer JW Kim, KH Nam, SH Ahn, DJ Park, HH Kim, SH Kim, H Chang, JO Lee, ... Gastric cancer 19, 42-52, 2016 | 282 | 2016 |
| Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer JY Cho, J Kim, JS Lee, YJ Kim, SH Kim, YJ Lee, YJ Cho, HI Yoon, JH Lee, ... Lung Cancer 125, 150-156, 2018 | 185 | 2018 |
| Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody KJ Suh, SH Kim, YJ Kim, M Kim, B Keam, TM Kim, DW Kim, DS Heo, ... Cancer Immunology, Immunotherapy 67, 459-470, 2018 | 155 | 2018 |
| Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC HJ Choi, BC Cho, JH Sohn, SJ Shin, SH Kim, JH Kim, NC Yoo Journal of neuro-oncology 91, 307-313, 2009 | 140 | 2009 |
| Artificial intelligence–powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non–small-cell lung cancer S Park, CY Ock, H Kim, S Pereira, S Park, M Ma, S Choi, S Kim, S Shin, ... Journal of Clinical Oncology 40 (17), 1916-1928, 2022 | 126 | 2022 |
| Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a … SH Kim, SJ Shin, KY Lee, H Kim, TI Kim, DR Kang, H Hur, BS Min, NK Kim, ... Annals of surgical oncology 20, 3407-3413, 2013 | 95 | 2013 |
| Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents U Jo, IS Senatorov, A Zimmermann, LK Saha, Y Murai, SH Kim, ... Molecular cancer therapeutics 20 (8), 1431-1441, 2021 | 76 | 2021 |
| Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors R Kim, B Keam, S Kim, M Kim, SH Kim, JW Kim, YJ Kim, TM Kim, YK Jeon, ... BMC cancer 19, 1-10, 2019 | 76 | 2019 |
| Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity SH Yoo, B Keam, M Kim, SH Kim, YJ Kim, TM Kim, DW Kim, JS Lee, ... ESMO open 3 (5), e000332, 2018 | 71 | 2018 |
| Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer J Shin, JH Chung, SH Kim, KS Lee, KJ Suh, JY Lee, JW Kim, JO Lee, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2019 | 70 | 2019 |
| Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First‐Line Palliative Chemotherapy S Hong, JH Lee, EK Chun, KI Kim, JW Kim, SH Kim, YG Lee, IG Hwang, ... The oncologist 25 (3), e502-e511, 2020 | 52 | 2020 |
| A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer YJ Kim, B Keam, CY Ock, S Song, M Kim, SH Kim, KH Kim, JS Kim, ... Lung cancer 136, 122-128, 2019 | 49 | 2019 |
| Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib M Jung, SH Kim, YJ Lee, S Hong, Y Kang, SK Kim, J Chang, SY Rha, ... Experimental and therapeutic medicine 2 (4), 685-693, 2011 | 48 | 2011 |
| Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors B Keam, CK Kang, KI Jun, SM Moon, KJ Suh, DW Lee, CY Ock, M Kim, ... Clinical Infectious Diseases 71 (2), 422-425, 2020 | 47 | 2020 |
| Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19) TM Kim, CY Ock, M Kim, SH Kim, B Keam, YJ Kim, DW Kim, JS Lee, ... Annals of Oncology 30, v628, 2019 | 42 | 2019 |
| Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor … S Park, B Keam, SH Kim, KH Kim, YJ Kim, JS Kim, TM Kim, SH Lee, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2015 | 34 | 2015 |
| Outcomes and recurrence patterns according to breast cancer subtypes in Korean women SHK Yoontaek Lee, Eunyoung Kang , Angela Soeun Lee, Hyunnam Baek, Eun-Kyu ... Breast Cancer Research and Treatment 151, 183, 2015 | 30 | 2015 |
| A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) SH Kim, HS Shim, J Cho, JH Jeong, SM Kim, YK Hong, JH Sung, SJ Ha, ... Lung Cancer 79 (3), 270-275, 2013 | 28 | 2013 |
| CpG island methylator phenotype and methylation of Wnt pathway genes together predict survival in patients with colorectal cancer SH Kim, KH Park, SJ Shin, KY Lee, TI Kim, NK Kim, SY Rha, JB Ahn Yonsei medical journal 59 (5), 588-594, 2018 | 27 | 2018 |
Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital在 snu.ac.kr 的电子邮件经过验证
